

Some polyneuropathies which have not been discussed elsewhere in this monograph deserve specific mention. Some of these are parts of clinical syndromes, while others are specific entities. Although mitochondrial diseases might well be considered to be “genetically determined,” they are also considered here. Peripheral neuropathy resulting from a mitochondrial defect associated with *MFN2* and *GDAP1* mutations has been addressed as part of the CMT group of peripheral nerve disorders and will not be readdressed here.

21.1 Neuropathy in Mitochondrial Diseases

21.1.1 Clinical Manifestations

Mitochondrial diseases are diagnosed when a disturbance of number, structure, or function of mitochondria is identified in association with an appropriate clinical picture. The spectrum of these diseases is growing rapidly. Mitochondria contain 2–10 copies of a 16,569 base-pair ring which encodes 13 proteins involved in oxidative phosphorylation and the special transfer RNA and ribosomal RNA required for intramitochondrial protein synthesis. Mitochondrial diseases usually arise as a consequence of mitochondrial DNA (mtDNA) mutations, but may also result from defects in nuclear DNA related to mitochondrial function. Although mitochondrial diseases may directly result in neuropathy, it is important to recognize that polyneuropathy may reflect a secondary associated condition (e.g., diabetes, renal failure, hypothyroidism) which may be part of some mitochondrial disorders (Finsterer 2005). Finsterer’s study (2005) of 108 patients with mitochondrial disease and polyneuropathy attributed 35 % directly to a primary mitochondrial pathogenesis.

Mitochondrial DNA defects are divided into deletions and point mutations (Zeviani and Antozzi 1992). Deletions are usually sporadic and typically manifest as a progressive external ophthalmoplegia (PEO) syndrome, either in isolation, with myopathy, or as the full Kearns–Sayre syndrome

(KSS). Point mutations are usually inherited (typically maternal transmission) and are associated with a variety of clinical phenotypes including MELAS (myopathy, encephalopathy, lactic acidosis, stroke-like episodes), MERRF (myoclonus epilepsy with ragged red fibers), and Leber hereditary optic neuropathy. Peripheral neuropathy defines several mitochondrial syndromes: (1) NARP (neuropathy, ataxia, and retinitis pigmentosa) caused by a missense mutation in the mitochondrial ATPase gene (*MTATP6*, Holt et al. 1990), (2) MNGIE (mitochondrial neurogastrointestinal encephalomyopathy) due to a thymidine phosphorylase (*TYMP*) gene defect, and (3) SANDO (sensory ataxic neuropathy, dysarthria, and ophthalmoparesis) thought, in some patients, to be caused by mutations in the mitochondrial polymerase γ (*POLG*) gene (Van Goethem et al. 2003). MNGIE is a particularly interesting neuropathy in which a nuclear-encoded defect in endothelial cell growth factor 1 (*ECGF1*) results in secondary mutations, deletions, and defects in mtDNA. Neuropathy has also been described in a variety of other mitochondrial syndromes, including MELAS, MERFF, PEO, and KSS (Nardin and Johns 2001). Leigh subacute necrotizing encephalopathy has been associated with several different mtDNA and nuclear DNA defects, illustrating the potential genetic heterogeneity of mitochondrial disease syndromes.

Neuropathy is present in 25–50 % of patients with most mitochondrial diseases (Eymard et al. 1991; Mizusawa et al. 1991; Yiannikas et al. 1986) and is usually mild, length dependent, with sensory alterations often predominating over motor deficits. Nerve conduction studies show axonal neuropathy, but demyelinating features have also been reported (Finsterer 2005). Peripheral neuropathy may occur (1) in mitochondrial disorders associated with defects in mitochondrial DNA maintenance or replication which may be caused by nuclear gene mutations (*POLG1*, *C10ORF2*, *TYMP*, and *MPV17*), (2) in the respiratory chain complexes particularly complex V associated with *MTATP6* mutations, and (3) in mitochondrial dynamics, i.e., the distribution of mitochondria by fission and fusion (*MFN2*, *GDAP1*

mutations) (Pareyson et al. 2013). A sense of the current complexity of mitochondriopathy in association with peripheral neuropathy is provided by the recent review by Pareyson and colleagues (2013).

Recent studies using mutant mice lacking Schwann cell Tfam, which controls the transcription, replication, and stability of mtDNA, show neuropathy characterized by the depletion of mtDNA, mitochondrial morphologic abnormalities, failure to create a normal electron transport chain, and respiration deficiency (Viader et al. 2013). In this mouse model, neuropathy was characterized by a preferential loss of small unmyelinated C fibers, followed by that of large myelinated axons and, ultimately, extensive demyelination of residual axons (Viader et al. 2013).

21.1.2 Pathology

Many single cases and small series of nerve biopsies and autopsies have been recorded in mitochondrial diseases including PEO/myopathy (Drachman 1968; Gemignani et al. 1982; Gonatas 1967; Markesbery 1979; Mizusawa et al. 1991; Peyronnard et al. 1980; Pezeshkpour et al. 1987; Schroder and Sommer 1991; Yiannikas et al. 1986), Leigh disease (Goebel et al. 1986; Jacobs et al. 1990; Schroder and Sommer 1991), MERRF (Mizusawa et al. 1991; Sasaki et al. 1983), MELAS (Mizusawa et al. 1991; Nicoll et al. 1993; Schroder and Sommer 1991), and MNGIE (Bardosi et al. 1987; Hirano et al. 1994, 2004; Li et al. 1991; Simon et al. 1990; Steiner et al. 1987; Threkeld et al. 1992; Uncini et al. 1993). As discussed below, the histological picture is non-specific and does not permit differentiation between the various mitochondrial diseases.

21.1.2.1 Light Microscopy

Nerve biopsies and autopsy reports in patients with PEO/myopathy syndrome have almost invariably revealed chronic depletion of myelinated fibers, the larger MFs usually being more severely affected. In one report, the study of myelin lamellar numbers vs. axonal diameter suggested the presence of axonal atrophy (Pezeshkpour et al. 1987). Regenerating clusters may be increased (Mizusawa et al. 1991; Peyronnard et al. 1980). Unmyelinated fibers are relatively spared, although observations such as increased numbers of denervated bands or collagen pockets suggest a mild involvement (Pezeshkpour et al. 1987; Yiannikas et al. 1986). Myelin alterations such as hypomyelination (Peyronnard et al. 1980), and segmental demyelination and remyelination with small onion-bulb (OB) formations (Mizusawa et al. 1991), have been frequently noted, but whether these are primary or secondary to axonal alterations has not been explored. The dramatic hypertrophic neuropathy described in Drachman's "Ophthalmoplegia Plus" paper (Drachman 1968) has not

been described by other workers, is clinically and histologically atypical for a mitochondrial disease, and most likely represents a superimposed peripheral nerve condition, perhaps multifocal neuropathy with persistent conduction block or CIDP.

Study of peripheral nerve in patients with Leigh disease has indicated preservation of myelinated and unmyelinated fiber densities, with thinly myelinated axons resulting from demyelination and remyelination (Goebel et al. 1986), or intrinsic hypomyelination (Jacobs et al. 1990; Schroder 1993). "Incipient" onion bulbs in Leigh disease were described by Goebel et al. (1986). Wallerian degeneration, active segmental demyelination, and dominant onion-bulb formation have not been noted.

In the point mutation syndromes, MELAS and MERRF, biopsies and autopsy studies have revealed chronic axonal depletion with some thinly myelinated fibers and occasional onion bulbs (Mizusawa et al. 1991; Nicoll et al. 1993; Robitaille et al. 1980). Sural nerve biopsies in patients with SANDO demonstrate severe loss of both large and small myelinated fibers with endoneurial fibrosis (Fadic et al. 1997).

Light microscopy in the MNGIE syndrome has also revealed chronic axonal depletion with variable regenerative activity and evidence of demyelination and remyelination. Dystrophic mitochondria with loss of cristae and paracrystalline inclusions have been described (Pareyson et al. 2013). The symptoms of MNGIE are an example of a mitochondrial syndrome caused by an mtDNA replication dysfunction that results from an imbalance in the mitochondrial nucleotide pool. Most often some small onion bulbs are seen, with individual reports describing a spectrum ranging from none to numerous onion bulbs. Whether the myelin alterations are primary or secondary remains unclear. Various workers have commented on nonspecific findings such as endoneurial vascular hyalinization and perineurial or endoneurial fibrosis.

21.1.2.2 Electron Microscopy

Of interest as to pathogenesis of the neuropathy is whether abnormal mitochondrial morphology can be detected in peripheral nerve as readily as it is in the muscle. Increased numbers or focal accumulations of mitochondria have occasionally been reported in Schwann cells (Peyronnard et al. 1980; Threkeld et al. 1992), and we have encountered an example in a case of neuropathy with genetically unestablished mitochondrial encephalomyopathy (Fig. 21.1a–c). Similar features were noted in neural endothelial and vascular smooth muscle cells in KSS and MELAS (Schroder and Sommer 1991), as previously described in other tissues (Ohama et al. 1987). Enlarged mitochondria have also been described in these mitochondrial neuropathies (Goebel et al. 1986; Hirano et al. 1994). Schroder and Sommer (1991) have




Fig. 21.1 Sural nerve in a patient with unestablished mitochondrial disease. Note that the Schwann cell collections of mitochondria (**a**, **b**) demonstrate one with a crystalline inclusion (*arrow*, **c**) (magnification: (**a**) 12,000 \times ; (**b**), 32,000 \times ; (**c**), 72,000 \times)

studied this issue most thoroughly and have concluded that enlarged mitochondria, some containing distorted cristae, are more common in mitochondrial cytopathies than in other neuropathies, but are not specific. Recent studies of a variety of a large number of mitochondrial peripheral neuropathies (Vital and Vital 2012) confirm the presence of ultrastructural mitochondrial changes including enlarged mitochondria with intertwined, or amputated cristae in Schwann cell cytoplasm. Increased numbers of Reich Pi granules have been

emphasized in some reports (Gemignani et al. 1982; Gonatas 1967).

A number of authors have described and illustrated nonmyelinating Schwann cells containing paracrystalline material surrounded by a double membrane, likely of mitochondrial origin (Schroder 1993; Yiannikas et al. 1986). However, such inclusions are not infrequently seen in a variety of non-mitochondrial peripheral nerve diseases (Schroder 1993).

Classic inclusions of the paracrystalline stacked bar variety have been illustrated in the nerve in only one instance (Li et al. 1991). Other, less characteristic but unusual intramitochondrial structures have been infrequently noted (Goebel et al. 1986; Pezeshkpour et al. 1987). In two patients with CMT type 6 and another with an idiopathic sensorimotor neuropathy, Sommer and Schroder (1989) illustrated enlarged mitochondria in Schwann cells of small MFs containing several linearly arrayed and closely apposed cristae with a paracrystalline material filling the intercrystal space. However, the “mitochondrial” nature of some CMT-6 patients remains speculative pending further evidence of mitochondrial dysfunction in this rare syndrome.

In one report of a patient with PEO/myopathy, examination of intramuscular nerve fibers revealed intra-axonal structures identical in ultrastructural appearance to Hirano bodies (Atsumi et al. 1980).

21.2 Adult Polyglucosan Body Disease

21.2.1 Clinical Manifestations

A number of entities are associated with tissue polyglucosan bodies, including type IV glycogenosis, phosphofructokinase deficiency, Lafora body disease, and normal aging (Cavanagh 1999). In our experience, polyglucosan bodies are found in about 3 % of sural nerve biopsies. In recent years, adult polyglucosan body disease (APGBD) has emerged as another distinct entity associated with characteristic inclusions (Cafferty et al. 1991; Gray et al. 1988; Karpati and Carpenter 1983; McDonald et al. 1993; Robitaille et al. 1980; Mochel et al. 2012). The APGBD syndrome includes adult-onset progressive upper motor neuron disease, urinary incontinence, dementia, and sensorimotor or pure motor peripheral neuropathy. Family history is positive in about one-third of cases, in a pattern suggestive of autosomal recessive inheritance. APGBD (Phenotype MIM#263570) is caused by mutation in the glycogen branching enzyme gene (*GBE1*; Gene/Locus MIM#607839). However, mutation in the same gene (*GBE1*) causes type IV glycogen storage disease (GSD IV; Phenotype MIM#232500), an early childhood disorder with systemic manifestations. Polyglucosan bodies are found throughout the central and peripheral nervous systems, as well as in myocardium and other nonneural tissues (Gray et al. 1988; Robitaille et al. 1980). Electrophysiological testing demonstrates an axonal neuropathy.

21.2.2 Pathology

A nerve biopsy showing polyglucosan bodies (PGBs) is commonly employed for the diagnosis of APGBD in life,

although axillary skin biopsy may be a reliable and less invasive procedure, showing large numbers of PGBs in the myoepithelial cells of apocrine glands (Busard et al. 1991; Milde et al. 2001).

Nerve biopsies reported in APGBD have shown from one to many polyglucosan bodies (Fig. 21.2a–c) per nerve fascicle cross section. Typically the bodies are intra-axonal, round, and range from 5 to 70 μm in diameter (Fig. 21.2a–c), may result in minimal change in the axon/myelin (Fig. 21.2d), or induce expansion of the axon dimensions with myelin thinning (Fig. 21.2e). Polyglucosan bodies are composed of aggregates of 6–8 nm diameter branched filaments (Fig. 21.2f) which lack a limiting membrane. The inclusions are seen in myelinated axons and, less frequently, in unmyelinated axons or Schwann cells (Cafferty et al. 1991; Vos et al. 1983). Longitudinal sections may indicate that the inclusions are elongated, and several may be seen within one axon (Cafferty et al. 1991; Robitaille et al. 1980). Deposits of similarly staining, but less distinctively organized, material can be seen in axons or other peripheral nerve cells including endothelial and perineurial cells, fibroblasts, and macrophages (Vos et al. 1983). Extracellular PGBs, surrounded by inflammatory cells, may result from the recent death of the axon previously containing that inclusion (Robitaille et al. 1980).

In most reported cases of APGBD axonal dropout ranging from mild to severe has been the dominant finding, the infrequency of debris-filled macrophages indicating a slow degenerative process. Regenerating clusters may be present. Prominent segmental demyelination is less commonly seen (Matsumuro et al. 1993; Vos et al. 1983). Axons with large inclusion bodies can show attenuation of surrounding myelin, but this may be due to axonal dilation, not demyelination and remyelination (Yoshikawa et al. 1990).

21.2.3 Pathogenesis

Polyglucosan bodies (including Lafora bodies and corpora amylacea) are made up almost entirely by glucose polymers, with only a small amount of protein, and some sulfate and phosphate groups (Stam and Roukema 1973; Steyaert et al. 1990; Milde et al. 2001). A study in alloxan diabetic rats demonstrated an intimate relationship between glycogen accumulation and formation of polyglucosan bodies (Powell et al. 1979). Seemingly identical inclusions are seen in type IV (brancher deficiency) glycogenosis (McMaster et al. 1979; Schroder et al. 1993). Thus, it seems reasonable to suppose that a disturbance of carbohydrate metabolism might result in the production of PGBs. Indeed, several Ashkenazi Jewish patients with APGBD have been shown to have a tissue-specific defect of brancher enzyme (Bruno et al. 1992; Lossos et al. 1991).




Fig. 21.2 Sural nerve in a 65-year-old patient with vasculitis. In the older age group, rare polyglucosan bodies (a–c) are of undetermined significance in the absence of an appropriate clinical context. Ultrastructural analysis demonstrates intra-axonal polyglucosan

bodies (d) which may dilate the axon and thin the myelin sheath (e). Ultrastructural analysis shows filamentous aggregates which are not membrane delimited (f) (a, H&E; b, c 1 µm thick plastic sections; d–f)




Fig. 21.2 (continued)

The mechanism of production of the neuropathy is unclear. Polyglucosan bodies are most commonly seen in the presence of an axonopathy (Busard et al. 1990); however, the axon is not necessarily disrupted by the inclusions, and in fact seems to be able to adapt to their presence (Yoshikawa et al. 1990). Whether the polyglucosan bodies, when massive in size or present in large numbers, cause the neuropathy or are an epiphenomenon of the metabolic defect that underlies the neuropathy remains unknown.

21.2.4 Differential Diagnosis

Our experience suggests that one or two polyglucosan bodies seen in a nerve biopsy specimen are a nonspecific finding with no diagnostic implications. We have noted polyglucosan bodies in 2–3 % of sural nerve biopsies, and others have reported that 8–15 % of unselected sural nerve biopsies in adults may show this finding (Averback and Langevin 1978; Busard et al. 1990). Intramuscular nerve twigs show polyglucosan bodies even more frequently (Averback and Langevin 1978; Bernsen et al. 1989; Fukuhara 1977). The incidence of PGBs in the nerve clearly rises with age, as with corpora amylacea in the central nervous system (Averback and Langevin 1978; Bernsen et al. 1989; Busard et al. 1990; Thomas et al. 1980), and there may be an association between the presence of non-specific CNS disease and the finding of peripheral nerve PGBs, even if a syndrome suggestive of APGBD is absent (Busard et al. 1990).

Observation of more than one PGB per nerve fascicle, of a PGB outside an axon, or of unusually large PGBs (>30 μm) should, however, lead to consideration of a number of disease entities, including APGBD, type IV glycogenosis (McMaster et al. 1979; Schroder and Sommer 1991), and Lafora disease (Bernsen et al. 1989; Busard et al. 1990). Similar suspicions should be raised by the finding of even a single PGB in a patient under the age of 5 (Busard et al. 1990) and perhaps under the age of 20 (Bernsen et al. 1989). PGBs have also been described in the setting of CIDP (Busard et al. 1990; Yoshikawa et al. 1990) and neuropathy in a diabetic (Mancardi et al. 1985). One patient with numerous PGBs in peripheral nerve and clinical features suggestive of APGBD who came to autopsy failed to reveal any unusual pathological features suggestive of a systemic accumulation of polyglucosan bodies (Gray et al. 1988).

21.3 Sensory Neuropathy Syndrome

21.3.1 Clinical Manifestations

The differential diagnosis of sensory neuropathy is considerable (Table 21.1). Once systemic malignancy and identifiable neuropathies are excluded, there remain a considerable number of patients in whom no explanation can be given and who have a relatively characteristic syndrome (Dalakas 1986; Griffin et al. 1990; Sobue et al. 1993; Windebank et al. 1990). These patients develop paresthesias, sensory loss, and

Table 21.1 Miscellaneous neuropathies

Neuropathy associated with mitochondrial disease
Adult polyglucosan body disease
Idiopathic sensory neuropathy/ganglionopathy
Hypereosinophilic syndrome
“Motor neuron” diseases
Critical illness polyneuropathy
Multiple symmetrical lipomatosis (Madelung disease)

sensory ataxia, but show no significant weakness. Sensory abnormalities may be distal and symmetrical, asymmetric, or segmental and can include the cranial nerves. As suggested by the sensory ataxia, large fiber damage often predominates, and small fiber function may be strikingly spared. Rate of progression varies widely, from days to years, and the morbidity ranges from insignificant to debilitation. Despite an extensive search, investigations reveal no evidence of malignancy, as confirmed with long-term follow-up (Windebank et al. 1990). There is an association with collagen disease, especially Sjögren syndrome (Griffin et al. 1990), but this accounts for a minority of patients (Dalakas 1986; Sobue et al. 1993; Windebank et al. 1990). CSF protein is normal or minimally elevated, and cell count is normal. Nerve conduction abnormalities suggest sensory axon damage with and minimal or no involvement of motor axons. No therapy has been of benefit, but a small proportion of patients show some spontaneous improvement (Dalakas 1986; Windebank et al. 1990).

21.3.2 Pathology

Sural nerve biopsy has been performed in many of these patients (Dalakas 1986; Griffin et al. 1990; Sobue et al. 1993; Windebank et al. 1990). Inflammation is not a feature, except in patients with Sjögren syndrome who may demonstrate perivascular mononuclear cell collections. Axon loss ranges from minimal to severe, and status ranging from very active to indolent. Regenerating clusters are infrequent. Large myelinated fibers may be most involved, but small myelinated and unmyelinated axons can also be lost (Sobue et al. 1993). Evidence of segmental demyelination and remyelination on teased fiber preparations has been interpreted as secondary to axonal atrophy (Sobue et al. 1993; Windebank et al. 1990).

The sural nerve findings in idiopathic sensory ganglionopathy are entirely nonspecific and cannot be distinguished from those in the paraneoplastic variant, although prominent inflammatory infiltration should suggest the presence of the Sjögren syndrome. Other potential causes of a sensory neuropathy (Table 21.1), especially vasculitis and CIDP, should be looked for.

21.3.3 Pathogenesis

A small number of autopsies and dorsal root ganglion biopsies have demonstrated inflammation and cell body loss in the spinal ganglia (Griffin et al. 1990). However, spinal ganglionitis would not explain the occasional evidence of mild motor fiber involvement (Windebank et al. 1990). Despite the association with autoimmune diseases, especially Sjögren syndrome, circulating antibodies reactive against spinal ganglion neurons have not been found (Griffin et al. 1990), in contrast to paraneoplastic polyganglionopathy. Inflammation may be seen in proximal nerve trunks, as contrasted with the absence of inflammation in nerve biopsy specimens (Sobue et al. 1993). The sural nerve histological findings described above suggest that a “sensory variant” of CIDP is not an important cause of this syndrome (Windebank et al. 1990).

21.4 Neuropathy in the Hypereosinophilic Syndrome

21.4.1 Clinical Manifestations

The hypereosinophilic syndrome (HES) is characterized by peripheral blood eosinophilia in the absence of known associated disease such as parasitic or fungal infection, granulomatous angitis, recognized allergic reaction, or malignancy (Moore et al. 1985). The clinical picture is of a multisystem disease with fevers, skin rash, pulmonary infiltrates, and cardiac disease (Chusid et al. 1975). Neuropathy may occur in as many as 50 % of patients, most often a mild symmetrical sensory polyneuropathy (Mondelli et al. 1993). However, a severe rapidly evolving axonal neuropathy, with distal predominance and some asymmetry, has been described as well (Dorfman et al. 1983; Grisold and Jellinger 1985; Sunohara et al. 1989). Response to steroids is usually gratifying.

21.4.2 Pathology

Nerve biopsy has been reported by several authors (Dorfman et al. 1983; Grisold and Jellinger 1985; Lupo et al. 1989; Monaco et al. 1988; Sunohara et al. 1989; Werner and Wolf 1990; Wichman et al. 1985). Most often a severe acute or chronic axonal neuropathy with little or no regenerative activity has been demonstrated. Large myelinated fibers may be more severely depleted. Biopsies in mildly affected or asymptomatic patients have shown only mild axonal loss or even a normal nerve (Vos et al. 1983; Wichman et al. 1985). Despite the usual presence of a marked peripheral eosinophilia, only one report describes an inflammatory neuropathy with significant vascular injury, and this case may have been an example of allergic eosinophilia, not an idiopathic HES

(Grisold and Jellinger 1985). Endoneurial edema was prominent in the two cases described by Monaco et al. (1988). In some reports, the authors have been impressed by the prominence of degranulated mast cells or thickening of capillary walls and endothelial cells (Lupo et al. 1989; Monaco et al. 1988).

21.4.3 Pathogenesis

Many of the manifestations of the HES are reminiscent of Churg–Strauss angiitis, and the possibility that this is a clinical variant must be considered. The neuropathy in HES is often asymmetric, suggestive of ischemic origin. However, most nerve biopsy material in the HES has shown a noninflammatory axonal neuropathy, which differs from the necrotizing angiitis of Churg–Strauss. Ischemia may be due to eosinophil-induced endothelial cell injury (Dorfman et al. 1983). A possible role of axonotoxic eosinophil products has been postulated and receives some support from experimental data (Lupo et al. 1989; Sunohara et al. 1989).

21.5 Motor Neuron Diseases

The motor neuron diseases, including ALS and spinal muscular atrophy, are generally said to spare sensory fibers, and as such one would expect sensory nerve biopsy to be normal. However, the literature suggests that this is an erroneous assumption and that although motor abnormalities completely overshadow the sensory changes, the latter do occur (Dyck et al. 1975; Mondelli et al. 1993).

21.5.1 Amyotrophic Lateral Sclerosis

Studies of sural or other sensory nerve biopsy in patients with ALS (Ben Hamida et al. 1987; Bradley et al. 1983; Dayan et al. 1969; di Trapani et al. 1986; Dyck et al. 1975; Heads et al. 1991; Tohgi et al. 1977) have not infrequently revealed slight but definite axonal depletion, sometimes with mild ongoing Wallerian degeneration, usually affecting large more than small MFs. Unmyelinated fibers have not been studied as closely, but these too seem to be affected (Ben Hamida et al. 1987; Heads et al. 1991). Regenerative activity, as evidenced by the presence of increased numbers of regenerating clusters, has at times been observed. Teased fiber studies have ranged from normal (Ben Hamida et al. 1987) to showing a marked increase in the incidence of segmental demyelination and remyelination, with abnormal internodes tending to be clustered along certain axons, suggesting a secondary demyelinating process (Heads et al. 1991). Neural inflammatory infiltrates are no more prominent in ALS than in normal nerves (Kerkoff et al. 1993). No

specific ultrastructural findings have been described, although nonspecific axonal degenerative changes have been commented upon (Dalakas 1986).

In early ALS, a morphometric comparison of eight patients and eight age-matched controls showed no significant reduction in MF density in sural/sensory nerves, but demonstrated a shift to the left in myelinated fiber diameter, i.e., axonal atrophy, and a bimodal unmyelinated fiber histogram, suggesting a degree of UF degeneration and regeneration (Heads et al. 1991). In contrast, with relatively late-stage ALS, a 30 % loss of myelinated fibers relative to controls was noted in sural nerves and an increase in the number of denervated Schwann cell subunits indicating unmyelinated fiber pathology (Bradley et al. 1983).

21.5.2 Other Motor Neuron Diseases

Distally accentuated axonal loss with axonal atrophy and secondary demyelination and remyelination has been found in X-linked bulbospinal neuronopathy (Kennedy syndrome), and these patients clearly demonstrate a loss of primary sensory neurons (Sobue et al. 1989). In distal spinal muscular atrophy, some studies have shown a chronic axonal process with prominent regenerating clusters (Gherardi et al. 1983), while in others the sensory nerves were entirely normal (Frequin et al. 1991; McLeod and Prineas 1971). The available information on proximal spinal muscular atrophies (Werdnig Hoffman, Kugelberg-Welander) indicates that axonal loss can occur in sensory nerves (Carpenter et al. 1978; Probst et al. 1981; Winder and Auer 1989).

The practical significance of these observations lies in two considerations. First, it is obviously inappropriate to use ALS or spinal muscular atrophy patients as “normal” sural nerve controls. Second, some patients with these diseases have atypical features, and nerve biopsy is performed in the search for a treatable illness. The finding of mild axonal degeneration and regeneration or slight segmental demyelination and remyelination does not exclude the diagnosis of motor neuron disease.

The possibility that a few motor axons run in the sural nerve, thus accounting for the observed axonal degeneration, seems unlikely (Carpenter et al. 1978), and loss of spinal ganglion neurons has been demonstrated in both ALS and spinal muscular atrophy (Carpenter et al. 1978; Kawamura et al. 1991; Marshall and Duchon 1975).

21.6 Critical Illness Polyneuropathy

The “critical illness” syndrome of systemic sepsis and multiple organ failure is characterized (Stevens et al. 2009) by prolonged periods of bacteremia and evidence of pulmonary, central nervous system, hepatic, cardiac, and renal

dysfunction. Neuropathy is being increasingly recognized as a part of this syndrome (recently reviewed by Koshy and Zochodne 2013), which is present in up to 70 % of these patients. Most often this emerges after periods ranging from days to weeks on a ventilator, when patients are unable to be weaned (Garcia Garcia et al. 1991; Gorson and Ropper 1993; Spitzer et al. 1992; Witt et al. 1991; Zochodne et al. 1987). Because of the difficulties associated with examining a critically ill patient, this neuropathy is often not suspected clinically, and the most reliable means of making the diagnosis is electrical testing, which reveals near normal nerve conduction velocities and decreased sensory nerve action potentials consistent with an axonal neuropathy of mild to marked severity. If systemic disease is controlled, patients can make an excellent recovery (Witt et al. 1991), although long-term studies have shown significant functional residua in some patients (Fletcher et al. 2003).

In critically ill patients, depending on the underlying illness, this syndrome may be clinically indistinguishable from a diffuse vasculitic neuropathy or severe Guillain-Barré syndrome. Biopsy might be performed so that a treatable diagnosis is not missed.

Pathological examination of autopsy and nerve biopsy material has demonstrated active axonal degeneration, distally enhanced, without a significant demyelinating component, nor any evidence of inflammation, serving to distinguish this neuropathy from the aforementioned alternatives (Zochodne et al. 1987). The absence of inflammation is a key element of the differential diagnosis in this setting, and its presence should suggest alternative diagnoses including vasculitis, GBS, and even endocarditis-associated neuropathy (Pamphlett and Walsh 1989).

No specific pathogenic mechanism has been identified, although nutritional and iatrogenic factors seem unlikely to be important (Zochodne et al. 1987). Most likely the metabolic changes associated with sepsis, especially high concentrations of various cytokines and increased levels of nitric oxide during sepsis (Angel et al. 2007), compounded by organ damage which promotes accumulation of toxic circulating substances and diminishes nutrition to stressed tissue, act together to cause axonal damage (Bolton et al. 1993).

21.7 Multiple Symmetrical Lipomatosis (Madelung Disease)

The essential feature of multiple symmetrical lipomatosis (MSL) is the presence of multiple axial and proximal limb non-encapsulated fat masses, most commonly around the neck, appearing during adult life (Enzi 1984). No consistent defects in lipid or glucose metabolism have been identified, but excessive alcohol intake has frequently been noted (Enzi 1984; Pollock et al. 1988). Sensorimotor polyneuropathy is often motor predominant, and autonomic features may be

prominent. Clinical and electrophysiological features suggest axonal neuropathy (Chalk et al. 1990; Enzi 1984). The polyneuropathy of MSL affects the majority of patients with MSL and often progresses to incapacitation (Saiz Hervas et al. 2000). A minority of patients demonstrate a multisystem disease with myopathy, cerebellar degeneration, and pyramidal signs, and a growing body of evidence suggests that at least some patients with multiple symmetrical lipomatosis suffer from a mitochondrial cytopathy (Berkovic et al. 1991; Holme et al. 1993; Klopstock et al. 1994) which may be exaggerated by alcohol (Saiz Hervas et al. 2000).

A small number of nerve biopsies of MSL have been reported (Chalk et al. 1990; Enzi et al. 1986; Pollock et al. 1988), and we have examined a case. Biopsy reveals a very indolent process causing depletion of myelinated axons, especially large myelinated fibers, with some regenerative cluster formation and no Wallerian degeneration (Fig. 21.3a). Unmyelinated fibers may be mildly depleted. In our experience, and in most other reports, no significant myelin alterations were noted, even with teased fibers (Chalk et al. 1990), although features of demyelination/remyelination have been noted in some cases, seemingly clustered along certain axons, suggestive of a primary axonal influence (Pollock et al. 1988).

Electron microscopic examination has not revealed any specific features. We have noted rare axons containing focal accumulations of normal appearing mitochondria (Fig. 21.3b), an intriguing finding given the evidence of mitochondrial dysfunction in these patients (*vide supra*). However, this was an uncommon finding and probably within the spectrum of nonspecific axonopathic alterations. The case we examined demonstrated numerous paracrystalline inclusions in muscle mitochondria, but these were completely absent in the nerve biopsy material. Pollock and colleagues (1988) noted a frequent honeycomb-like degeneration of inner myelin lamellae.

21.8 Traumatic Injuries

Traumatic injury to the nerve takes a number of forms. Chronic nerve compression which occurs in entrapment neuropathy is characterized by focal loss of myelin and, often, increased numbers of Renaut bodies (collections of fibroblast-like cells surrounded by mucoid extracellular matrix). Chronic compression may produce fibrosis of the underlying nerve accompanied by endoneurial edema, demyelination, remyelination, and axon loss. Morton neuroma, resulting from chronic compression of interdigital nerves of the foot, is a fusiform enlargement or thickening of the intact but chronically compressed nerve. Similarly, constriction of the lateral femoral cutaneous nerve by fascia/inguinal ligament is thought to produce pain, numbness, and paresthesia in the territory of the outer and anterior thigh, a syndrome




Fig. 21.3 Madelung disease. Diffuse dropout of MFs of all sizes is seen (a). The finding of rare intra-axonal accumulations of normal mitochondria is of undetermined significance (b). The muscle biopsy

in this patient showed numerous abnormal mitochondria with paracrystalline inclusions (a, b 23,660 \times) (plastic, tissue courtesy of Dr. Y. Yucel)

designated meralgia paresthetica. This syndrome is often seen in obese patients of either gender between the fourth and sixth decades of life and usually improves spontaneously (reviewed in Arnold and Elsheikh 2013).

Irrespective of the suggestion of neoplasm by the name “neuroma,” this is a nonneoplastic reactive proliferation of axons, fibroblasts, and Schwann and perineurial cells which may develop in somatic or visceral nerves, spontaneously or as the result of prior surgery or injury. Traumatic damage to peripheral nerve results in efficient regeneration in some cases but, in others, particularly those with injury in which there is loss of nerve continuity, regeneration is interrupted and frustrated. These swollen nerve segments represent the neuroma (i.e., traumatic or amputation neuroma). Damage to the nerve trunk may reflect focal proximal interruption by neuropathy, particularly vasculitis, vertebral collapse, or the results of prior surgery in which nerves were intentionally or inadvertently sectioned.

The resultant pathological response represents a combination of degenerative and regenerative responses resulting

in disorganized aggregates of collagen and minifascicles (arrows, Fig. 21.4a, b) of regenerating and sprouted axons (Fig. 21.4c) searching for their distal connections (Fig. 21.4d). Sprouted axons are typically ensheathed by Schwann cells shown by S100 immunohistochemistry (Fig. 21.4e) which may myelinate axons or surround them as unmyelinated axons. Minifascicles contain thinly myelinated and unmyelinated axons (Fig. 21.4f) and are surrounded by perineurial cells which stain with EMA (arrows, Fig. 21.4g).

Neuroma tissue has been found to contain increased levels of the chemorepulsive protein semaphorin 3A, which may increase fasciculation and inhibit organized neurite outgrowth (Tannemaat et al. 2007). Large clusters of frustrated regenerating axons suggest the failure to eliminate supernumerary axons in regenerating nerve. Neuromas may be painful to touch or movement which may reflect alterations in sodium channels in constituent axons. This discovery holds the promise for targeted blockade of NaV1.7 or ERK1/2 as a therapeutic strategy for amelioration of chronic pain that




Fig. 21.4 Neuroma, traumatic sections of neuroma composed of mini-fascicles (*arrows, a*) surrounded by collagenous processes (*b*, trichrome) which contain clusters of axons (*c*, neurofilament immunohistochemistry). The distal end of injured nerve stump shows mini-fascicles arising from nerve trunk (*d*, collagen IV stain). S100

immunohistochemistry highlights Schwann cells within mini-fascicles (*e*). Mini-fascicles contain small and large myelinated axons with a thin perineurial rim (*arrow, f*) which is highlighted by EMA immunohistochemistry (*g*)




Fig. 21.4 (continued)




Fig. 21.5 Meralgia paresthetica, sections of lateral femoral cutaneous nerve show marked axon loss and prominently hyalinized vasculature (arrow, a). Ultrastructural examination confirms the wholesale

loss of axons and increased endoneurial collagen (a, 1 μ m thick plastic section, 600 \times ; b, 3,000 \times)

often follows nerve injury and formation of neuromas and may be extrapolated to other conditions with intractable pain (Persson et al. 2011). Resection of the distal portion of the proximal stump and apposition of proximal and distal stumps or transplantation of a nerve graft may be curative.

The lateral femoral cutaneous (LFC) nerve is a pure sensory nerve which passes under the inguinal ligament and supplies sensation to the skin over the anterior and lateral portion of the thigh. Meralgia paresthetica is a syndrome of numbness, paresthesia, and pain associated with compression of the LFC which is increased in incidence in diabetes, obesity, pregnancy, external compression by clothes, or prolonged positioning during surgery (Parisi et al. 2011; Arnold and Elsheikh 2013). We have seen one example of LFC nerve resected from a patient with meralgia paresthetica which was characterized by marked axon loss accompanied by hyalinized endoneurial blood vessels (Fig. 21.5a, b).

21.9 Perineurioma

Intraneural perineurioma is a benign intraneural neoplasm consisting of aggregates of perineurial cells which superficially resemble onion-bulb neuropathy. Although

chromosome 22 alterations are seen in perineurioma, it is not associated with neurofibromatosis NF1 or NF2 (Emory et al. 1995). There is no history of prior traumatic injury associated with perineurioma which typically involves somatic nerves in the extremities rather than cranial nerves. Perineurioma may involve individual or multiple fascicles of nerve, with plexiform growth in some cases (Fig. 21.6a–c). The tumors are composed of multiple concentric layers of perineurial processes (Fig. 21.6b) forming coarse structures superficially resembling onion bulbs. Neurofilament immunohistochemistry illustrates that concentric processes variably surround axons (Fig. 21.6d), which are often found in clusters, forming larger, coarser structures than true onion bulbs. The processes are immunoreactive for epithelial membrane antigen (EMA, arrows, Fig. 21.6e). Mitoses are uncommon and Ki67 immunostaining shows a modest frequency (5–15 %, Scheithauer et al. 2010). Plastic sections (Fig. 21.6f) confirm the broad coarse composition of the concentric processes. Ultrastructurally, processes with patchy basal lamina, unbranched processes, and numerous pinocytotic vesicles are seen (Fig. 21.6g), as expected in perineurium-derived cells (Emory et al. 1995; Scheithauer et al. 2010).




Fig. 21.6 Perineurioma. This intraneural tumor is composed of coarse concentric processes involving some fascicles and sparing others (*arrow*, **a**). The coarse concentric processes seen at higher magnification in (**b**) are reminiscent of onion bulbs. Plexiform growth is frequent (**c**). Immunolocalization of neurofilament immunoreactivity shows clumps of axons within perineurial processes and others without axonal cores (**d**). The perineurial origin of the tumor is confirmed by EMA

histochemistry (**e**). A 1 μm thick plastic section further characterizes the coarse nature and arrangement of the tumor cells (**f**). Ultrastructure illustrates the unbranched nature of the perineurial processes, focal basement membranes, and pinocytotic vesicles (**g**) (**a**, **b**, H&E; **c**, HPS trichrome; **d**, **e**, neurofilament and EMA immunohistochemistry, respectively; **f**, 1 μm thick plastic section; **g**, electron micrograph, 2,500 \times)




Fig. 21.6 (continued)

Separation of intraneural perineuriomas from true onion-bulb neuropathies is usually not difficult since true onion-bulb neuropathies are often hereditary, consist of delicate processes which are S100 immunoreactive but are not immunoreactive for EMA, and typically do not involve only portions of nerves sparing some fascicles and not others.

References

- Angel MJ, Bril V, Shannon P et al (2007) Neuromuscular function in survivors of the acute respiratory distress syndrome. *Can J Neurol Sci* 34:427–432
- Arnold WD, Elsheikh BH (2013) Entrapment neuropathies. *Neurol Clin* 31:405–424
- Atsumi T, Yakamura Y, Sato T, Ikuta F (1980) Hirano bodies in the axon of peripheral nerves in a case with progressive external ophthalmoplegia with multisystemic involvement. *Acta Neuropathol* 49:95–100
- Averback P, Langevin H (1978) Corpora amylacea of the lumbar spinal cord and peripheral nervous system. *Arch Neurol* 35:95–96
- Bardosi A, Creutzfeldt W, DiMauro S et al (1987) Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) with partial deficiency of cytochrome C oxidase. A new mitochondrial multisystem disorder. *Acta Neuropathol* 74:248–253
- Ben Hamida M, Letaief F, Hentati F, Ben Hamida C (1987) Morphometric study of the sensory nerve in classical (or Charcot disease) and juvenile amyotrophic lateral sclerosis. *J Neurol Sci* 78:313–329
- Berkovic SF, Andermann F, Shoubridge EA et al (1991) Mitochondrial dysfunction in multiple symmetrical lipomatosis. *Ann Neurol* 29:566–569
- Bernsen RAJAM, Busard HLSM, Ter Lakk HJ et al (1989) Polyglucosan bodies in intramuscular motor nerves. *Acta Neuropathol* 77:629–633
- Bolton CF, Young GB, Zochodne DW (1993) The neurological complications of sepsis. *Ann Neurol* 33:94–100
- Bradley WG, Good P, Rasool CG, Adelman LS (1983) Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. *Ann Neurol* 14:267–277
- Bruno C, Servidei S, Shanske S et al (1992) Glycogen branching enzyme in adult polyglucosan body disease. *Neurology* 42(Suppl 3):230 (abstr)
- Busard HLSM, Gabreels-Festen AAWM, Van't Hoff MA et al (1990) Polyglucosan bodies in sural nerve biopsies. *Acta Neuropathol* 80:554–557
- Busard HLSM, Gabreels-Festen AAWM, Renier WO et al (1991) Adult polyglucosan body disease: the diagnostic value of axilla skin biopsy. *Ann Neurol* 29:448–451
- Cafferty MS, Lovelace RE, Hays AP et al (1991) Polyglucosan body disease. *Muscle Nerve* 14:102–107
- Carpenter S, Karpati G, Rothman S et al (1978) Pathological involvement of primary sensory neurons in Werdnig-Hoffman disease. *Acta Neuropathol* 42:91–97
- Cavanagh JB (1999) Corpora amylacea and the family of polyglucosan diseases. *Brain Res* 29:265–295
- Chalk CH, Mills KR, Jacobs JM, Donaghy M (1990) Familial multiple symmetric lipomatosis with peripheral neuropathy. *Neurology* 40:1246–1250
- Chusid MJ, Dale DC, West BD, Wolff SM (1975) The hypereosinophilic syndrome. Analysis of 14 cases with review of the literature. *Medicine* 54:1–27
- Dalakas MC (1986) Chronic idiopathic ataxic neuropathy. *Ann Neurol* 19:545–554
- Dayan AD, Graveson GS, Illis S, Robinson PK (1969) Schwann cell damage in motoneuron disease. *Neurology* 19:242–246
- di Trapani G, David P, La Cara A et al (1986) Morphological studies of sural nerve biopsies in the pseudopolyneuropathic form of amyotrophic lateral sclerosis. *Clin Neuropathol* 5:134–138
- Dorfman LJ, Ransom BR, Forno LS, Kelts A (1983) Neuropathy in the hypereosinophilic syndrome. *Muscle Nerve* 6:291–298
- Drachman DA (1968) Ophthalmoplegia plus. The neurodegenerative disorders associated with progressive external ophthalmoplegia. *Arch Neurol* 18:654–674
- Dyck PJ, Stevens JC, Mulder DW, Espinosa RE (1975) Frequency of nerve fiber degeneration of peripheral motor and sensory neurons in amyotrophic lateral sclerosis: morphometry of deep and superficial peroneal nerves. *Neurology* 25:781–785
- Emory TS, Scheithauer BW, Hirose T et al (1995) Intraneural perineurioma. A clonal neoplasm associated with abnormalities of chromosome 22. *Am J Clin Pathol* 103:696–704
- Enzi G (1984) Multiple symmetric lipomatosis: an updated clinical report. *Medicine* 63:56–64
- Enzi G, Angelini C, Negrin P et al (1986) Sensory, motor, and autonomic neuropathy in patients with multiple symmetrical lipomatosis. *Medicine* 64:388–393
- Eymard B, Penicaud A, Leger JM et al (1991) Etude clinique et électrophysiologique du nerf périphérique dans 28 cas de maladie mitochondriale. *Rev Neurol* 147:508–512
- Fadic R, Russell JA, Vedanarayanan VV et al (1997) Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. *Neurology* 49:239–245
- Finsterer J (2005) Mitochondrial neuropathy. *Clin Neurol Neurosurg* 107:181–186
- Fletcher SN, Kennedy DD, Ghosh IR et al (2003) Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. *Crit Care Med* 31:1012–1016
- Frequin ST, Gabreels FJ, Gabreels-Festen AAWM, Joosten EMG (1991) Sensory axonopathy in hereditary distal spinal muscular atrophy. *Clin Neurol Neurosurg* 93:323–326
- Fukuhara N (1977) Intra-axonal corpora amylacea in the peripheral nerve seen in a healthy woman. *J Neurol Sci* 34:423–426
- Garcia Garcia A, Lopez Messa J, Aparicio Duque R (1991) Peripheral polyneuropathy complicating conditions of sepsis and multi organ failure. *Electromyogr Clin Neurophysiol* 31:181–186
- Gemignani F, Juvarrá G, Marbini A et al (1982) Polyneuropathy in progressive external ophthalmoplegia. *Eur Neurol* 21:181–188
- Gherardi R, Bouche P, Escourolle R et al (1983) Peroneal muscular atrophy. Part 2. Nerve biopsy studies. *J Neurol Sci* 61:401–416
- Goebel HH, Bardosi A, Friede RL (1986) Sural nerve biopsy studies in Leigh's subacute necrotizing encephalomyelopathy. *Muscle Nerve* 9:165–173
- Gonatas NK (1967) A generalized disorder of nervous system, skeletal muscle and heart resembling Refsum's disease and Hurler's syndrome. *Am J Med* 42:169–178
- Gorson KC, Ropper AH (1993) Acute respiratory failure neuropathy: a variant of critical illness polyneuropathy. *Crit Care Med* 21:267–271
- Gray F, Gherardi R, Marshall A et al (1988) Adult polyglucosan body disease. *J Neuropathol Exp Neurol* 47:459–474
- Griffin JW, Cornblath DR, Alexander E et al (1990) Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjogren's syndrome. *Ann Neurol* 27:304–315
- Grisold W, Jellinger K (1985) Multifocal neuropathy with vasculitis in hypereosinophilic syndrome: an entity or drug induced effect. *J Neurol* 231:301–306
- Heads T, Pollock M, Robertson A et al (1991) Sensory nerve pathology in amyotrophic lateral sclerosis. *Acta Neuropathol* 82:316–320

- Hirano M, Silvestri G, Blake DM et al (1994) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. *Neurology* 44:721–727
- Hirano M, Nishigaki Y, Marti R (2004) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. *Neurologist* 10:8–17
- Holme E, Larsson NG, Oldfors A et al (1993) Multiple symmetric lipomas with high levels of mtDNA with the tRNA(lys) A→G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. *Am J Hum Genet* 52:551–556
- Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA (1990) A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. *Am J Hum Genet* 46:428–433
- Jacobs JM, Harding NN, Lake BD et al (1990) Peripheral neuropathy in Leigh's disease. *Brain* 113:447–462
- Karpati G, Carpenter S (1983) The clinical spectrum of adult polyglucosan body disease. *Neurology* 33(Suppl 2):246 (abstr)
- Kawamura Y, Dyck PJ, Masatake S et al (1991) Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol* 40:667–675
- Kerkoff A, Troost D, Louwse ES et al (1993) Inflammatory cells in the peripheral nervous system in motor neuron disease. *Acta Neuropathol* 85:560–565
- Klopstock T, Naumann M, Schalke B et al (1994) Multiple symmetric lipomatosis: abnormalities in complex IV and multiple deletions in mitochondrial DNA. *Neurology* 44:862–866
- Koshy K, Zochodne DW (2013) Chapter 44. Neuromuscular complications of critical illness. In: Said G, Krarup C (eds) *Handbook of clinical neurology. Peripheral nerve disorders*, vol 115 (3rd series). Elsevier BV, Amsterdam, pp 759–780
- Li V, Hostein J, Romero N et al (1991) Chronic intestinal pseudo-obstruction with myopathy and ophthalmoplegia: a muscular biochemical study of a mitochondrial disorder. *Dig Dis Sci* 37:456–463
- Lossos A, Barash V, Soffer D et al (1991) Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. *Ann Neurol* 30:655–662
- Lupo I, Daniele O, Raimondo D et al (1989) Peripheral neuropathy in the hypereosinophilic syndrome: a case report. *Eur Neurol* 29:269–272
- Mancardi GL, Schenone A, Tabaton M et al (1985) Polyglucosan bodies in sural nerve of diabetic patient with polyneuropathy. *Acta Neuropathol* 66:83–86
- Marksbery WR (1979) Lactic acidemia, mitochondrial myopathy, and basal ganglia calcification. *Neurology* 29:1057–1061
- Marshall A, Duchon LW (1975) Sensory system involvement in infantile spinal muscular atrophy. *J Neurol Sci* 26:349–359
- Matsumuro K, Izumo S, Minauchi Y et al (1993) Chronic demyelinating neuropathy and intra-axonal polyglucosan bodies. *Acta Neuropathol* 86:95–99
- McDonald TD, Faust PL, Bruno C et al (1993) Polyglucosan body disease simulating amyotrophic lateral sclerosis. *Neurology* 43:785–790
- McLeod JG, Prineas JW (1971) Distal type of chronic spinal muscular atrophy - clinical, electrophysiological and pathological studies. *Brain* 94:703–714
- McMaster KR, Powers JM, Hennigar GR et al (1979) Nervous system involvement in type IV glycogenosis. *Arch Pathol Lab Med* 103:105–111
- Milde P, Guccion JG, Kelly J et al (2001) Adult polyglucosan body disease - diagnosis by sural nerve and skin biopsy. *Arch Pathol Lab Med* 125:519–522
- Mizusawa H, Ohkoshi N, Watanabe M, Kanazawa I (1991) Peripheral neuropathy of mitochondrial myopathies. *Rev Neurol* 147:501–507
- Mochel F, Schiffmann R, Steenweg ME et al (2012) Polyglucosan body disease: natural history and key magnetic resonance imaging findings. *Ann Neurol* 72:433–441
- Monaco S, Lucci B, Laperchia N et al (1988) Polyneuropathy in hypereosinophilic syndrome. *Neurology* 38:494–496
- Mondelli M, Rossi A, Passero S, Guazzi GC (1993) Involvement of peripheral sensory fibers in amyotrophic lateral sclerosis: electrophysiological study of 64 cases. *Muscle Nerve* 16:166–172
- Moore PM, Harley JB, Fauci AS (1985) Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. *Ann Intern Med* 102:109–114
- Nardin RA, Johns DR (2001) Mitochondrial dysfunction and neuromuscular disease. *Muscle Nerve* 24:170–191
- Nicoll JA, Moss TH, Love S et al (1993) Clinical and autopsy findings in two cases of MELAS presenting with stroke-like episodes but without clinical myopathy. *Clin Neuropathol* 12:38–43
- Ohama E, Ohara S, Ikuta F et al (1987) Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalopathy. *Acta Neuropathol* 74:226–233
- Pamphlett R, Walsh J (1989) Infective endocarditis with inflammatory lesions in the peripheral nervous system. *Acta Neuropathol* 78:101–104
- Pareyson D, Piscoquito G, Moroni I et al (2013) Peripheral neuropathy in mitochondrial disorders. *Lancet Neurol* 12:1011–1124
- Parisi TJ, Mandrekar J, Dyck PJ et al (2011) Meralgia paresthetica: relation to obesity, advanced age, and diabetes mellitus. *Neurology* 77:1538–1542
- Persson AK, Gasser A, Black JA, Waxman SG (2011) Nav1.7 accumulates and co-localizes with phosphorylated ERK1/2 within transected axons in early experimental neuromas. *Exp Neurol* 230:273–279
- Peyronnard JM, Charron L, Bellavance A, Marchand L (1980) Neuropathy and mitochondrial myopathy. *Ann Neurol* 7:262–268
- Pezeshkpour G, Krarup C, Buchtal F et al (1987) Peripheral neuropathy in mitochondrial disease. *J Neurol Sci* 77:285–304
- Pollock M, Nicholson GI, Nukada H et al (1988) Neuropathy in multiple symmetric lipomatosis. Madelung's disease. *Brain* 111:1157–1171
- Powell HC, Ward HW, Garrett RS et al (1979) Glycogen accumulation in the nerves and kidney of chronically diabetic rats. A quantitative electron microscope study. *J Neuropathol Exp Neurol* 38:114–127
- Probst A, Ulrich J, Bischoff A et al (1981) Sensory gangliopathy in infantile spinal muscular atrophy. Light and electron microscopic findings in two cases. *Neuropediatrics* 12:215–231
- Robitaille Y, Carpenter S, Karpati G, DiMauro S (1980) A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes. *Brain* 103:315–336
- Saiz Hervas E, Martin Llorens M, Alvarez L (2000) Peripheral neuropathy as the first manifestation of Madelung's disease. *Br J Dermatol* 143:684–686
- Sasaki H, Kuzuhara S, Kanazawa I et al (1983) Myoclonus, cerebellar disorder, neuropathy, mitochondrial myopathy and ACTH deficiency. *Neurology* 33:1288–1293
- Scheithauer BW, Woodruff JM, Spinner RJ (2010) Chapter 12. Peripheral nerve sheath tumors. In: Perry A, Brat DJ (eds) *Practical surgical neuropathology*. Churchill Livingstone, Philadelphia, pp 235–285
- Schmidt RE, Bilbao JM (in press) Chapter 21. Diseases of peripheral nerve. In: Love S, Perry A, Ironside J, Budka H (eds) *Greenfield's neuropathology*, 9th edn
- Schroder JM (1993) Neuropathy associated with mitochondrial disorders. *Brain Pathol* 3:177–190
- Schroder JM, Sommer C (1991) Mitochondrial abnormalities in human sural nerves: fine structural evaluation of cases with mitochondrial myopathy, hereditary and non-hereditary neuropathies, and review of the literature. *Acta Neuropathol* 82:471–482

- Schroder JM, May R, Shin YS et al (1993) Juvenile hereditary polyglucosan body disease with complete branching enzyme deficiency (type IV glycogenosis). *Acta Neuropathol* 85:419–430
- Simon LT, Horoupian DS, Dorfman LJ et al (1990) Polyneuropathy, ophthalmoplegia, leukoencephalopathy, and intestinal pseudo-obstruction: POLIP syndrome. *Ann Neurol* 28:349–360
- Sobue G, Hashizume Y, Mukai E et al (1989) X-linked recessive bulbospinal neuronopathy. A clinico-pathological study. *Brain* 112:209–232
- Sobue G, Yasuda T, Kachi T et al (1993) Chronic progressive sensory ataxic neuropathy: clinicopathologic features of idiopathic and Sjogren's syndrome-associated cases. *J Neurol* 240:1–7
- Sommer C, Schroder JM (1989) Hereditary motor and sensory neuropathy with optic atrophy. *Arch Neurol* 46:972–977
- Spitzer AR, Giancarlo T, Maher L et al (1992) Neuromuscular causes of prolonged ventilator dependency. *Muscle Nerve* 15:682–686
- Stam FC, Roukema PA (1973) Histochemical and biochemical aspects of corpora amylacea. *Acta Neuropathol* 25:95–102
- Steiner I, Steinberg A, Argov Z et al (1987) Familial progressive neuronal disease and chronic idiopathic intestinal pseudo-obstruction. *Neurology* 37:1046–1050
- Stevens RD, Marshall SA, Cornblath DR et al (2009) A framework for diagnosing and classifying intensive care unit-acquired weakness. *Crit Care Med* 37:S299–S308
- Steyaert A, Cisse S, Merhi Y et al (1990) Purification and polypeptide composition of corpora amylacea from aged human brain. *J Neurosci Methods* 31:59–64
- Sunohara N, Furukawa S, Nishio T et al (1989) Neurotoxicity of human eosinophils towards peripheral nerves. *J Neurol Sci* 92:1–7
- Tannemaat MR, Korecka J, Ehlert EM et al (2007) Human neuroma contains increased levels of semaphorin 3A, which surrounds nerve fibers and reduces neurite extension in vitro. *J Neurosci* 27:14260–14264
- Thomas PK, King RHM, Sharma AK (1980) Changes with age in the peripheral nerves of the rat. An ultrastructural study. *Acta Neuropathol* 52:1–6
- Threkeld AB, Miller NR, Golnik KC et al (1992) Ophthalmic involvement in myo-neuro-gastrointestinal encephalopathy syndrome. *Am J Ophthalmol* 114:322–328
- Tohgi H, Tsukagoshi H, Toyokura Y (1977) Quantitative changes of sural nerves in various neurological diseases. *Acta Neuropathol* 38:95–101
- Uncini A, Servidei S, Silvestri G et al (1993) Ophthalmoplegia, demyelinating neuropathy, leukoencephalopathy, myopathy, and gastrointestinal dysfunction with multiple deletions of mitochondrial DNA: a mitochondrial multisystem disorder in search of a name. *Muscle Nerve* 17:667–674
- Van Goethem G, Martin JJ, Dermaut B et al (2003) Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. *Neuromuscul Disord* 13:133–142
- Viader A, Sasaki Y, Kim S et al (2013) Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. *Neuron* 77:886–898
- Vital A, Vital C (2012) Mitochondria and peripheral neuropathies. *J Neuropathol Exp Neurol* 71:1036–1046
- Vos AJ, Joosten EM, Gabreels-Festen AA (1983) Adult polyglucosan body disease: clinical and nerve biopsy findings in two cases. *Ann Neurol* 13:440–444
- Werner RA, Wolf LL (1990) Peripheral neuropathy associated with the hypereosinophilic syndrome. *Arch Phys Med Rehabil* 71:433–435
- Wichman A, Buchtal F, Pezeshkpour GH et al (1985) Peripheral neuropathy in hypereosinophilic syndrome. *Neurology* 35:1140–1145
- Windebank AJ, Blexrud MD, Dyck PJ et al (1990) The syndrome of acute sensory neuropathy: clinical features and electrophysiologic and pathologic changes. *Neurology* 40:584–591
- Winder TR, Auer RN (1989) Sensory neuron degeneration in familial Kugelberg-Welander disease. *Can J Neurol Sci* 16:67–70
- Witt NJ, Zochodne DW, Bolton CF et al (1991) Peripheral nerve function in sepsis and multiple organ failure. *Chest* 99:176–184
- Yiannikas C, McLeod JG, Pollard JD, Baverstock J (1986) Peripheral neuropathy associated with mitochondrial myopathy. *Ann Neurol* 20:249–257
- Yoshikawa H, Dyck PJ, Poduslo PJ, Giannini C (1990) Polyglucosan body axonal enlargement increases myelin spiral length but not lamellar number. *J Neurol Sci* 98:107–117
- Zeviani M, Antozzi C (1992) Defects of mitochondrial DNA. *Brain Pathol* 2:121–132
- Zochodne DW, Bolton CF, Wells GA et al (1987) Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. *Brain* 110:819–842